Результаты поиска - Gee‐Chen Chang
- Отображение 1 - 20 результаты of 49
- Перейти на следующую страницу
-
1
Genetic Polymorphism of XRCC1 Arg399Gln Is Associated With Survival in Non–Small-Cell Lung Cancer Patients Treated With Gemcitabine/Platinum по Wei‐Yu Liao, Jin‐Yuan Shih, Gee‐Chen Chang, Yu-Kai Cheng, James Chih‐Hsin Yang, Yuh‐Min Chen, Chong‐Jen Yu
Опубликовано 2012Artigo -
2
Digoxin Suppresses Tumor Malignancy through Inhibiting Multiple Src-Related Signaling Pathways in Non-Small Cell Lung Cancer по Sheng-Yi Lin, Hsiu-Hui Chang, Yi-Hua Lai, Ching‐Hsiung Lin, Min-Hsuan Chen, Gee‐Chen Chang, Meng-Feng Tsai, Jeremy J.W. Chen
Опубликовано 2015Artigo -
3
Curcumin Induces EGFR Degradation in Lung Adenocarcinoma and Modulates p38 Activation in Intestine: The Versatile Adjuvant for Gefitinib Therapy по Jen‐Yi Lee, Yee-Ming Lee, Gee‐Chen Chang, Sung‐Liang Yu, Wan-Yu Hsieh, Jeremy J.W. Chen, Huei‐Wen Chen, Pan‐Chyr Yang
Опубликовано 2011Artigo -
4
P2.14-59 Osimertinib in EGFR T790M Advanced NSCLC: Analysis of Uncommon/Complex EGFR Mutations in a Real-World Study (ASTRIS) по Parneet Cheema, Antonio Passaro, Charles E. Martin, Marcello Tiseo, K. Park, Gee‐Chen Chang, Yang Hu, Byoung Chul Cho, Margarida S. Miranda, A. Fernandes, H. Freitas
Опубликовано 2019Artigo -
5
-
6
-
7
PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients по Kuo-Hsuan Hsu, Jeng‐Sen Tseng, Tsung‐Ying Yang, Kun‐Chieh Chen, Kang‐Yi Su, Sung‐Liang Yu, Jeremy J.W. Chen, Yen-Hsiang Huang, Gee‐Chen Chang
Опубликовано 2022Artigo -
8
-
9
-
10
-
11
A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma по Tony Mok, Sarayut Lucien Geater, Wu‐Chou Su, Eng-Huat Tan, James Chih‐Hsin Yang, Gee‐Chen Chang, May Han, Philip Komarnitsky, Francis Payumo, Jennifer Garrus, Sandra Close, Keunchil Park
Опубликовано 2016Artigo -
12
Dynamic Plasma EGFR Mutation Status as a Predictor of EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Adenocarcinoma по Jeng‐Sen Tseng, Tsung‐Ying Yang, Chi‐Ren Tsai, Kun‐Chieh Chen, Kuo-Hsuan Hsu, Meen-Hsin Tsai, Sung‐Liang Yu, Kang‐Yi Su, Jeremy J.W. Chen, Gee‐Chen Chang
Опубликовано 2014Artigo -
13
Surface α-Enolase Promotes Extracellular Matrix Degradation and Tumor Metastasis and Represents a New Therapeutic Target по Kuan-Chung Hsiao, Neng-Yao Shih, Hsun-Lang Fang, Tze‐Sing Huang, Ching-Chuan Kuo, Pei‐Yi Chu, Yi‐Mei Hung, Shao-Wen Chou, Yi-Yuan Yang, Gee‐Chen Chang, Ko-Jiunn Liu
Опубликовано 2013Artigo -
14
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program по Solange Peters, Alessandra Curioni‐Fontecedro, Hovav Nechushtan, Jin‐Yuan Shih, Wei‐Yu Liao, Oliver Gautschi, Vito Spataro, Mojca Unk, James Chih‐Hsin Yang, Robert M. Lorence, Philippe Carrière, A. Cseh, Gee‐Chen Chang
Опубликовано 2018Artigo -
15
MA02.03 ASTRIS: A Real World Treatment Study of Osimertinib in Patients with EGFR T790M-Positive NSCLC по Yi‐Long Wu, Byoung Chul Cho, Qing Zhou, Gee‐Chen Chang, Liyan Jiang, Giulio Metro, Claudio Martín, Gilberto de Castro, Johan Vansteenkiste, David Vicente, A. Milner, James R. Rigas, Y. Chen, Mariano Provencio
Опубликовано 2018Artigo -
16
Pretreatment Epidermal Growth Factor Receptor (<i>EGFR</i>) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Ca... по Kang‐Yi Su, Hsuan‐Yu Chen, Ker-Chau Li, Min‐Liang Kuo, James Chih‐Hsin Yang, Wing‐Kai Chan, Bing‐Ching Ho, Gee‐Chen Chang, Jin‐Yuan Shih, Sung‐Liang Yu, Pan‐Chyr Yang
Опубликовано 2012Artigo -
17
HOXA5 Inhibits Metastasis via Regulating Cytoskeletal Remodelling and Associates with Prolonged Survival in Non-Small-Cell Lung Carcinoma по Chi-Chung Wang, Kang‐Yi Su, Hsuan‐Yu Chen, So-Yi Chang, Chi-Fan Shen, Chia-Hung Hsieh, Qi-Sheng Hong, Ching-Cheng Chiang, Gee‐Chen Chang, Sung‐Liang Yu, Jeremy J.W. Chen
Опубликовано 2015Artigo -
18
The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarc... по Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng‐Sen Tseng, Kun‐Chieh Chen, Chia-Hung Hsu, Kang‐Yi Su, Jeremy J.W. Chen, Huei‐Wen Chen, Sung‐Liang Yu, Tsung‐Ying Yang, Gee‐Chen Chang
Опубликовано 2018Artigo -
19
Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report по James Chih‐Hsin Yang, Frances A. Shepherd, Dong‐Wan Kim, Gyeong‐Won Lee, Jong Seok Lee, Gee‐Chen Chang, Sung Sook Lee, Yu‐Feng Wei, Yun Gyoo Lee, Gianluca Laus, Barbara Collins, Francesca Pisetzky, Leora Horn
Опубликовано 2019Artigo -
20
Инструменты поиска:
Связанные темы
Medicine
Cancer
Internal medicine
Biology
Lung cancer
Oncology
Genetics
Gene
Cancer research
Epidermal growth factor receptor
Adenocarcinoma
Gefitinib
Gastroenterology
Biochemistry
Confidence interval
T790M
Erlotinib
Genotype
Single-nucleotide polymorphism
Pathology
Genome-wide association study
Osimertinib
Cell biology
Genetic association
Metastasis
Adverse effect
Environmental health
Bioinformatics
Chemotherapy
Clinical endpoint